Lupin has informed about submission of a Press Release as regards receipt of USFDA approval for Tadalafil Tablets USP, 20 mg to market a generic version of Eli Lilly and Company's Adcirca Tablets, 20 mg. This is considered as a disclosure pursuant to Regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.